Roche Holding AG Net Worth 2012-2025 | RHHBY
Interactive chart of historical net worth (market cap) for Roche Holding AG (RHHBY) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Roche Holding AG net worth as of February 06, 2026 is $367.58B.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $367.580B | $76.450B |
| Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1000.386B | 43.71 |
| Johnson & Johnson (JNJ) | United States | $578.207B | 22.22 |
| AbbVie (ABBV) | United States | $394.887B | 22.34 |
| Novartis AG (NVS) | Switzerland | $330.425B | 17.42 |
| Merck (MRK) | United States | $302.633B | 13.59 |
| Novo Nordisk (NVO) | Denmark | $212.713B | 12.18 |
| Pfizer (PFE) | United States | $154.765B | 8.43 |
| Sanofi (SNY) | France | $116.658B | 10.80 |
| Innoviva (INVA) | United States | $1.630B | 8.16 |